Sensitivity surveillance of <I>Haemophilus influenzae</I> isolates for several antibiotics in Gifu prefecture (2006)
-
- KAERIYAMA MAKOTO
- Working Group of Tokai Anti-biogram study group Research Laboratories of Toyama Chemical Co., Ltd
-
- MIZUNAGA SHINGO
- Working Group of Tokai Anti-biogram study group Research Laboratories of Toyama Chemical Co., Ltd
-
- MITSUYAMA JUNICHI
- Working Group of Tokai Anti-biogram study group Research Laboratories of Toyama Chemical Co., Ltd
-
- YAMAOKA KAZUKIYO
- Working Group of Tokai Anti-biogram study group Gifu University of Medical Science
-
- ASANO YUKO
- Working Group of Tokai Anti-biogram study group Department of Clinical Laboratory Medicine, Ogaki Municipal Hospital
-
- SAWAMURA HARUKI
- Working Group of Tokai Anti-biogram study group Gifu University School of Medicine
-
- SUEMATSU HIROYUKI
- Working Group of Tokai Anti-biogram study group Clinical Laboratories Chuno Kosei Hospital
-
- TERAJI MAYUMI
- Working Group of Tokai Anti-biogram study group Hida Medical Laboratory
-
- TSUCHIYA MASAKO
- Working Group of Tokai Anti-biogram study group Clinical Laboratories, Tohno Kosei Hospital
-
- HASHIDO HIKONORI
- Working Group of Tokai Anti-biogram study group Takayama Red Cross Hospital
-
- MATSUKAWA YOKO
- Working Group of Tokai Anti-biogram study group Clinical Laboratories, Gifu Prefectual Tajimi Hospital
-
- MATSUBARA SHIGENORI
- Working Group of Tokai Anti-biogram study group Matsubara Otorhinolaryngology Clinic
-
- MIYABE TAKANORI
- Working Group of Tokai Anti-biogram study group Clinical Laboratories, Tokai Central Hospital
-
- WATANABE KUNITOMO
- Working Group of Tokai Anti-biogram study group Division of Anaerobe Research, Life Science Research Center, Gifu University
-
- MIKAMO HIROSHIGE
- Working Group of Tokai Anti-biogram study group Department of Infection Control and Prevention, Aichi Medical University
Bibliographic Information
- Other Title
-
- 阜県下で分離されたインフルエンザ菌の感受性サーベイランス(2006)
- 岐阜県下で分離されたインフルエンザ菌の感受性サーベイランス(2006)
- ギフ ケンカ デ ブンリサレタ インフルエンザキン ノ カンジュセイ サーベイランス 2006
Search this article
Abstract
We investigated the susceptibility to antibacterials of 194 strains of Haemophilus influenzae isolated from medical facilities in Gifu prefecture between 2005 and 2006, and compared these results with those of 280 strains of H.influenzae isolated between 1999 and 2000. Additionally, the strains that had been separated between 2005 and 2006 were examined for β-lactamase (BL) production, the muta tion of ftsI gene coding for PBP3, the bla gene coding for TEM type of BL and the serotype.<BR>Referring to the CLSI breakpoint, H.influenzae strains were classified into the following categories: (1) β-lactamase-negative ampicillin-susceptible (BLNAS) strains, which showed BL negative, ampicillin (ABPC) and ampicillin/sulbactam (ABPC/SBT)-MIC<1μg/ml,(2) β-lactamase producing ampicillinresistant (BLPAR) strains, which showed BL producing and ABPC/SBT-MIC<2μg/ml,(3) β-lactamasenegative ampicillin-resistant (BLNAR) strains, which showed BL negative, ABPC and ABPC/SBT-MIC>μ g/ml,(4) β-lactamase-producing amoxicillin/clavulanic acid-resistant (BLPACR) strains, which showed BL producing and ABPC/SBT-MIC>2μg/ml.<BR>The prevalence of each resistance class were 71.8% for BLNAS, 7.9% for BLPAR, 19.6% for BLNAR and 0.7% for BLPACR in strains isolated between 1999 and 2000. But they were 38.1% for BLNAS, 4.6% for BLPAR, 54.6% for BLNAR and 2.6% for BLPACR in strains isolated between 2005 and 2006, indicating that the percentage of BLNAS and BLPAR decreased and that of BLNAR and BLPACR increased from 1999-2000 to 2005-2006.<BR>On the basis of ftsI substitutions and having bla gene, the strains isolated between 2005 and 2006 were classified into the following distribution: 24.2% for gBLNAS, 4.1% for gBLPAR, 10.8% for gLow-BLNAR, 57.7% for gBLNAR, and 3.1% for gBLPACR-II. Ratio of BLNAR belonging to gBLNAR and gLow-BLNAR based on the ftsI substitutions and having bla gene was higher than that based on the susceptibility pattern.<BR>The MIC50 and MIC90 for those strains isolated between 2005 and 2006 were as follows; 0.0039, 0.0156μg/ml for garenoxacin, 0.0078, 0.0156μg/ml for tosufloxacin and ciprofloxacin, 0.0156, 0.0313μg/ml for levofloxacin, 0.0313, 0.0625μg/ml for norfloxacin, 0.0625, 0.25μg/ml for piperacillin/ tazobactam, 0.0625, 0.5μg/ml for piperacillin, 0.125, 0.25μg/ml for ceftriaxone and cefditoren, 0.5, 1μg/ml for cefteram, chloramphenicol and tetracycline, 0.5, 2μg/ml for cefotaxime, 2, 8μg/ml for ampicillin, ampicillin/sulbactam and cefdinir. In comparison with the values for the strains isolated between 1999 and 2000, the MIC50s of β-lactam for the strains isolated between 2005 and 2006 increased over 4 times.
Journal
-
- The Japanese Journal of Antibiotics
-
The Japanese Journal of Antibiotics 61 (4), 195-208, 2008
Japan Antibiotics Research Association
- Tweet
Details 詳細情報について
-
- CRID
- 1390282680471870848
-
- NII Article ID
- 10021928537
- 130004396082
-
- NII Book ID
- AN00002626
-
- COI
- 1:CAS:528:DC%2BD1cXhtVGgtbfI
-
- ISSN
- 21865477
- 03682781
-
- NDL BIB ID
- 9637258
-
- Text Lang
- ja
-
- Data Source
-
- JaLC
- NDL
- CiNii Articles
-
- Abstract License Flag
- Disallowed